MLH1 and Lynch syndrome: To this end, we have now approached the approximately 250 individuals with known diagnoses of MLH1- and MSH6-Lynch syndrome in our regional population of 3 million and will extend the offer to the around 1500 Lynch syndrome carriers being followed by our team as part of the CaPP3 aspirin dose non-inferiority trial [EUdract no. 2014-000411-14].